Stille presents strong Q3 2026 financial results with 16.5% organic growth
Net sales reached MSEK 170.6 and EBITDA before non-recurring items rose to MSEK 33.7, signaling continued profitability and strategic positioning.
See the latest news and media coverage for Stille. We track all announcements, press releases, and industry mentions in real time, all in one place.
Surgical instrument and C-arm table manufacturer
stille.seLast updated
In short: Stille reported 16.5% organic growth as Q3 2026 sales and EBITDA rose.
Net sales reached MSEK 170.6 and EBITDA before non-recurring items rose to MSEK 33.7, signaling continued profitability and strategic positioning.
Gross margin 48.4%, EBITDA MSEK 36.5, and CEO notes improving product availability and M&A opportunities.
Net sales reach MSEK 179.1, up 38.5%. Gross margin is 49.1%. EBITDA before non-recurring items is MSEK 38.5.
Net sales reach MSEK 174.9, up 8.5%. Gross margin is 51.1%. EBITDA before non-recurring items is MSEK 38.1. Expects solid growth in 2026.
The medical technology company Stille reports increased turnover and a higher operating result during the third quarter compared to the same period last year.
Stille AB (OSTO:STIL) posted 22.9% revenue growth to SEK170.6 million with EBIT before non-recurring items up 42%, while flagging elevated backorders and a tariff refund...
The medical technology company Stille, which manufactures surgical instruments and operating tables, reports an operating result for the second quarter of 2026 of...
The medical technology company Stille reported an operating profit of 16.6 million kronor (25.7) for the second quarter of 2025. Net sales were 124.7 million kronor (142.6). Cash flow from continuing...
Track Stille and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Stille and other trending companies.